171 related articles for article (PubMed ID: 24887335)
21. [Oxcarbazepine in the treatment of epilepsy. A review and update].
Horga de la Parte JF; Horga A
Rev Neurol; 2006 Jan 16-31; 42(2):95-113. PubMed ID: 16450324
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy.
Jang Y; Yoon S; Kim TJ; Lee S; Yu KS; Jang IJ; Chu K; Lee SK
Sci Rep; 2021 Mar; 11(1):6370. PubMed ID: 33737678
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
Flesch G; Czendlik C; Renard D; Lloyd P
Drug Metab Dispos; 2011 Jun; 39(6):1103-10. PubMed ID: 21389120
[TBL] [Abstract][Full Text] [Related]
24. The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study.
Wegner I; Wilhelm AJ; Sander JW; Lindhout D
Epilepsy Behav; 2013 Oct; 29(1):217-21. PubMed ID: 23995050
[TBL] [Abstract][Full Text] [Related]
25. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium.
Mazzucchelli I; Onat FY; Ozkara C; Atakli D; Specchio LM; Neve AL; Gatti G; Perucca E
Epilepsia; 2006 Mar; 47(3):504-9. PubMed ID: 16529613
[TBL] [Abstract][Full Text] [Related]
26. First Analysis of the Association Between CYP3A4/5, ABCB1 Genetic Polymorphisms and Oxcarbazepine Metabolism and Transport in Chinese Epileptic Patients with Oxcarbazepine Monotherapy and Bitherapy.
Wang P; Yin T; Ma HY; Liu DQ; Sheng YA; Zhou BT
J Pharm Pharm Sci; 2015; 18(3):256-65. PubMed ID: 26517132
[TBL] [Abstract][Full Text] [Related]
27. [Population pharmacokinetics of lamotrigine in Chinese children with epilepsy].
Zhang S; Wang L; Lu W
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Apr; 10(2):105-9. PubMed ID: 18433522
[TBL] [Abstract][Full Text] [Related]
28. Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis.
Bae EK; Lee J; Shin JW; Moon J; Lee KJ; Shin YW; Kim TJ; Shin D; Jang IJ; Lee SK
Seizure; 2016 Apr; 37():8-12. PubMed ID: 26908152
[TBL] [Abstract][Full Text] [Related]
29. Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy.
Kim DW; Gu N; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Kim HS; Oh J; Lee SK
Epilepsia; 2012 Jan; 53(1):e9-12. PubMed ID: 22091603
[TBL] [Abstract][Full Text] [Related]
30. Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy.
Park KJ; Kim JR; Joo EY; Seo DW; Hong SB; Ko JW; Kim SR; Huh W; Lee SY
Clin Neuropharmacol; 2012; 35(1):40-4. PubMed ID: 22246398
[TBL] [Abstract][Full Text] [Related]
31. [Pharmacokinetic variability of oxcarbazepine in epileptic patients].
Viola MS; Bercellini MA; Saidón P; Rubio MC
Medicina (B Aires); 2000; 60(6):914-8. PubMed ID: 11436701
[TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetics of valproate in Chinese children with epilepsy.
Jiang DC; Wang L; Wang YQ; Li L; Lu W; Bai XR
Acta Pharmacol Sin; 2007 Oct; 28(10):1677-84. PubMed ID: 17883957
[TBL] [Abstract][Full Text] [Related]
33. Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers.
Antunes Nde J; Wichert-Ana L; Coelho EB; Della Pasqua O; Alexandre Junior V; Takayanagui OM; Tozatto E; Marques MP; Lanchote VL
Eur J Clin Pharmacol; 2016 Feb; 72(2):195-201. PubMed ID: 26514967
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the Effects of Ketoconazole and Voriconazole on the Pharmacokinetics of Oxcarbazepine and Its Main Metabolite MHD in Rats by UPLC-MS-MS.
Chen X; Gu E; Wang S; Zheng X; Chen M; Wang L; Hu G; Cai JP; Zhou H
J Chromatogr Sci; 2016 Mar; 54(3):334-42. PubMed ID: 26499119
[TBL] [Abstract][Full Text] [Related]
35. Plasma level monitoring of oxcarbazepine in epileptic patients.
González-Esquivel DF; Ortega-Gavilán M; Alcántara-López G; Jung-Cook H
Arch Med Res; 2000; 31(2):202-5. PubMed ID: 10880728
[TBL] [Abstract][Full Text] [Related]
36. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.
Carlsson KC; Hoem NO; Glauser T; Vinks AA
Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311
[TBL] [Abstract][Full Text] [Related]
37. A comparison of the efficacy and tolerability of oxcarbazepine oral suspension between infants and children with epilepsy: a retrospective chart review at a single medical center in Taiwan.
Wei SH; Liu CC; Fan PC
Paediatr Drugs; 2014 Feb; 16(1):83-9. PubMed ID: 24081427
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects.
Antunes NJ; van Dijkman SC; Lanchote VL; Wichert-Ana L; Coelho EB; Alexandre Junior V; Takayanagui OM; Tozatto E; van Hasselt JGC; Della Pasqua O
Eur J Pharm Sci; 2017 Nov; 109S():S116-S123. PubMed ID: 28528287
[TBL] [Abstract][Full Text] [Related]
39. Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain.
Clinckers R; Smolders I; Michotte Y; Ebinger G; Danhof M; Voskuyl RA; Della Pasqua O
Br J Pharmacol; 2008 Dec; 155(7):1127-38. PubMed ID: 18836479
[TBL] [Abstract][Full Text] [Related]
40. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group.
Glauser TA; Nigro M; Sachdeo R; Pasteris LA; Weinstein S; Abou-Khalil B; Frank LM; Grinspan A; Guarino T; Bettis D; Kerrigan J; Geoffroy G; Mandelbaum D; Jacobs T; Mesenbrink P; Kramer L; D'Souza J
Neurology; 2000 Jun; 54(12):2237-44. PubMed ID: 10881246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
